Cellectar Biosciences receives patent protection for cancer drug
Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion
Global M&A by the Numbers: Q2 2022
Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms
Infographic 2022 Top Tech Trends Shaping Corporations
Cellectar Biosciences Inc. received a patent covering the method of use for CLR 1603 to treat breast, lung, colorectal and prostate cancers as well as associated cancer stem cells.
The patent protection will last through the end of 2035.